With ABPI move, Carole Longson lets go of purse strings and starts tugging at them

25 January 2018

A long-standing leader in health technology assessment (HTA) in the UK and internationally has taken a step across the divide to become a leading lobbyist for pharma.

As director of the Centre for Health Technology Evaluation for cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE), Carole Longson has long been concerned with saving money for the UK’s National Health Service (NHS) as it adopts new medicines.

After being with NICE for 18 years, she is moving to become the chief scientific officer (CSO) of the Association of the British Pharmaceutical Industry (ABPI), the trade group for pharma in the UK and a long-term campaigner for more money to be invested into funding innovative medical research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK